---
document_datetime: 2025-11-04 09:31:09
document_pages: 11
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/jivi-epar-procedural-steps-taken-scientific-information-after-authorisation-archived_en.pdf
document_name: jivi-epar-procedural-steps-taken-scientific-information-after-authorisation-archived_en.pdf
version: success
processing_time: 6.7336451
conversion_datetime: 2025-12-26 21:09:17.493521
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Jivi

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                                                                                                | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| X/0033/G             | This was an application for a group of variations. Annex I_2.(c) Change or addition of a new strength/potency B.III.2.b - Change to comply with Ph. Eur. or with a national pharmacopoeia of a Member State - Change | 25/04/2025                          | 25/06/2025                                  | SmPC, Labelling and PL           |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

<!-- image -->

|         | to comply with an update of the relevant monograph of the Ph. Eur. or national pharmacopoeia of a Member State B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |            |            |                                  |                                                               |
|---------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|---------------------------------------------------------------|
| II/0034 | Extension of indication to include treatment and prophylaxis of bleeding in previously treated patients ≥ 7 years of age with haemophilia A for Jivi, based on integrated analysis results from Part A of the Alfa- PROTECT study (21824) and PROTECT Kids main study (15912). Alfa-PROTECT is a Phase 3, single- group treatment, open-label study to evaluate the safety of BAY 94-9027 infusions for prophylaxis and treatment of bleeding in previously treated children aged 7 to <12 years with severe haemophilia A. PROTECT Kids is a multi-center, Phase 3, non- controlled, open-label trial to evaluate the pharmacokinetics, safety, and efficacy of BAY 94- 9027 for prophylaxis and treatment of bleeding in previously treated children (age <12 years) with severe haemophilia A. As a consequence, sections 2, 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 3.3 of the RMP has also been submitted. In addition, the Marketing authorisation holder (MAH) took the opportunity to update the list of local representatives in the Package Leaflet. Furthermore, the PI is brought in line with the latest | 25/04/2025 | 02/06/2025 | SmPC, Annex II, Labelling and PL | Please refer to Scientific Discussion 'Jivi-H-C-004054-II-34' |

<div style=\"page-break-after: always\"></div>

|           | C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |            |     |                     |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|---------------------|
| IB/0032/G | This was an application for a group of variations. B.I.d.1.b.1 - Stability of AS - Change in the storage conditions - Change to more restrictive storage conditions of the AS B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS B.I.a.4.b - Change to in-process tests or limits applied during the manufacture of the AS - Addition                                                                                                                                                                                                                              | 05/09/2024 | n/a | of a new in-process |
| II/0031/G | This was an application for a group of variations. B.I.b.1.f - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Change outside the approved specifications limits range for the AS B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement for the AS or a starting | 11/04/2024 | n/a | or addition)        |

<div style=\"page-break-after: always\"></div>

|                     | material/intermediate                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |            |            |                                  |                                                                                                                                                                                                                                                                    |
|---------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10732 /202308 | Periodic Safety Update EU Single assessment - damoctocog alfa pegol                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 11/04/2024 | n/a        |                                  | PRAC Recommendation - maintenance                                                                                                                                                                                                                                  |
| II/0028             | C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority                                                                                                                                                                                                                                                                                                                                                                                                  | 28/09/2023 | n/a        |                                  |                                                                                                                                                                                                                                                                    |
| IB/0029             | B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition)                                                                                                                                                                                                                                                                                                                                                                                                         | 25/09/2023 | n/a        |                                  |                                                                                                                                                                                                                                                                    |
| R/0027              | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 26/04/2023 | 23/06/2023 | SmPC, Annex II, Labelling and PL | Based on the review of data on quality, safety and efficacy, the CHMP considered that the benefit-risk balance of Jivi in the approved indication remains favourable and therefore recommended the renewal of the marketing authorisation with unlimited validity. |
| II/0025/G           | This was an application for a group of variations. B.II.b.1.f - Replacement or addition of a manufacturing site for part or all of the manufacturing process of the FP - Site where any manufacturing operation(s) take place, except batch release, batch control, and secondary packaging, for sterile medicinal products (including those that are aseptically manufactured) excluding biological/ immunological medicinal products B.II.e.1.b.2 - Change in immediate packaging of the finished product - Change in type/addition of a new | 17/11/2022 | n/a        |                                  |                                                                                                                                                                                                                                                                    |

<div style=\"page-break-after: always\"></div>

|           | biological/immunological medicinal products                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |            |     |                                         |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----------------------------------------|
| II/0024/G | This was an application for a group of variations. B.I.b.2.d - Change in test procedure for AS or starting material/reagent/intermediate - Substantial change to or replacement of a biological/immunological/immunochemical test method or a method using a biological reagent for a biological AS B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate B.I.a.4.z - Change to in-process tests or limits applied during the manufacture of the AS - Other variation B.I.b.2.d - Change in test procedure for AS or starting material/reagent/intermediate - Substantial change to or replacement of a biological/immunological/immunochemical test method or a method using a biological reagent for a biological AS B.I.b.1.f - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Change outside the approved specifications limits range for the AS B.I.b.2.d - Change in test procedure for AS or starting material/reagent/intermediate - Substantial change to or replacement of a test | 17/11/2022 | n/a | biological/immunological/immunochemical |

<div style=\"page-break-after: always\"></div>

|           | or a method using a biological reagent for a biological AS B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition) B.I.b.2.d - Change in test procedure for AS or starting material/reagent/intermediate - Substantial change to or replacement of a biological/immunological/immunochemical test method or a method using a biological reagent for a biological AS B.II.d.1.e - Change in the specification parameters and/or limits of the finished product - Change outside the approved specifications limits range   |            |     | method   |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|----------|
| IB/0026   | B.II.z - Quality change - Finished product - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 03/10/2022 | n/a |          |
| II/0023   | B.II.e.1.b.2 - Change in immediate packaging of the finished product - Change in type/addition of a new container - Sterile medicinal products and biological/immunological medicinal products                                                                                                                                                                                                                                                                                                                                                                                                           | 30/06/2022 | n/a |          |
| II/0019/G | This was an application for a group of variations. B.I.b.1.f - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Change outside the approved specifications limits range for the AS B.II.d.1.e - Change in the specification parameters and/or limits of the finished product - Change outside the approved specifications limits range                                                                                                                                                                                                            | 22/04/2022 | n/a |          |

<div style=\"page-break-after: always\"></div>

| PSUSA/10732 /202108   | Periodic Safety Update EU Single assessment - damoctocog alfa pegol                                                                                                                                                                                                                             | 07/04/2022   | n/a        |             | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                            |
|-----------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0022               | B.I.a.4.z - Change to in-process tests or limits applied during the manufacture of the AS - Other variation                                                                                                                                                                                     | 24/11/2021   | n/a        |             |                                                                                                                                                                                                                                                                                                                                                              |
| N/0020                | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                | 20/10/2021   | 23/06/2023 | PL          |                                                                                                                                                                                                                                                                                                                                                              |
| IB/0018               | C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation                                                                                                                                                   | 22/07/2021   | n/a        |             |                                                                                                                                                                                                                                                                                                                                                              |
| PSUSA/10732 /202008   | Periodic Safety Update EU Single assessment - damoctocog alfa pegol                                                                                                                                                                                                                             | 09/04/2021   | n/a        |             | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                            |
| II/0017               | Submission of the final report from the pharmacokinetic study 19742 comparing the pharmacokinetic parameters of Jivi vs. Adynovi. C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority                 | 18/03/2021   | n/a        |             | Submission of the final report from the pharmacokinetic study 19742 comparing the pharmacokinetic parameters of Jivi vs. Adynovi. Results of the study did not change the PK profile or benefit/risk assessment for Jivi, therefore no change of the Jivi SmPC is needed. Please refer to Scientific Discussion 'Product Name-H-C- Product Number-II-Var.No' |
| II/0015               | Update of sections 4.8 and 5.1 of the SmPC to reflect the final study report of the long-term extension study 15912 (PROTECT Kids) in children. This extension study is a category 3 study of the Jivi RMP. The MAH took the oportunity to update the list of local representatives in the PIL. | 12/11/2020   | 18/12/2020 | SmPC and PL | SmPC new text As a result of this variation, sections 4.8 and 5.1 of the SmPC were updated to include the following: Section 4.8: 'In the paediatric study, 59/73 patients < 12 years continued in the extension study. Median (range) total time in study (main study + extension) was 5.8 (1.0-                                                            |

<div style=\"page-break-after: always\"></div>

|                     | C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                                                                                                                                                                                                                                           |            |     | 6.6) years with a median of 430 (range 98-671) ED per subject, 39 subjects were treated for =/> 5 years. The median number of exposure days to Jivi per subject was 95237 (min-max: 1-698) for all subjects in the clinical studies. Overall, in both studies 75 patients were observed for a treatment duration of more than 5 years.' Section 5.1: 'For 59 patients who continued in the extension study the overall median (Q1;Q3) ABR during the extension period was 1.64 (0.5, 3.1). For 30 patients ≥ 12 years at the end of the extension study, the median (Q1; Q3) ABR was 1.76 (0.5; 3.3),' which is in accordance with the presented results in the final study report and thus accepted. For more information, please refer to the Summary of Product Characteristics.   |
|---------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10732 /202002 | Periodic Safety Update EU Single assessment - damoctocog alfa pegol                                                                                                                                                                                                                                                                                                                                                                         | 01/10/2020 | n/a | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| II/0014             | Addition of the following additional site for quality control testing of the drug product in the US: Bayer HealthCare LLC, 800 Dwight Way, Berkeley, CA 94710 (USA). B.II.b.2.b - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place for a biol/immunol product and any of the test methods at the site is a biol/immunol method | 10/09/2020 | n/a |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |

<div style=\"page-break-after: always\"></div>

| II/0012             | Update of sections 4.8 and 5.1 of the SmPC to reflect the final study results of the long-term extension study 13024 (PROTECT VIII). This extension study is a category 3 study of the Jivi RMP (MEA-005). The PL is updated to reflect a change in the contact of a local representative. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data   | 03/09/2020   | 18/12/2020   | SmPC and PL                      |                                   |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|----------------------------------|-----------------------------------|
| IAIN/0013           | C.I.11.a - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of wording agreed by the competent authority                                                                                                                                                                                                                      | 31/07/2020   | n/a          |                                  |                                   |
| PSUSA/10732 /201908 | Periodic Safety Update EU Single assessment - damoctocog alfa pegol                                                                                                                                                                                                                                                                                                                                            | 12/03/2020   | n/a          |                                  | PRAC Recommendation - maintenance |
| II/0004             | C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority                                                                                                                                                                                                                                                                  | 06/02/2020   | n/a          |                                  |                                   |
| IAIN/0010           | C.I.11.a - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of wording agreed by the competent authority                                                                                                                                                                                                                      | 04/02/2020   | n/a          |                                  |                                   |
| IB/0008/G           | This was an application for a group of variations. B.II.e.5.a.2 - Change in pack size of the finished product - Change in the number of units (e.g.                                                                                                                                                                                                                                                            | 20/12/2019   | 18/12/2020   | SmPC, Annex II, Labelling and PL |                                   |

<div style=\"page-break-after: always\"></div>

|           | tablets, ampoules, etc.) in a pack - Change outside the range of the currently approved pack sizes B.II.e.5.a.2 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change outside the range of the currently approved pack sizes B.II.e.5.a.2 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change outside the range of the currently approved pack sizes B.II.e.5.a.2 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change outside the range of the currently approved pack sizes B.II.e.5.a.2 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change outside the range of the currently approved pack sizes   |            |     |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| IA/0009/G | This was an application for a group of variations. B.I.a.4.a - Change to in-process tests or limits applied during the manufacture of the AS - Tightening of in-process limits B.III.2.a.2 - Change of specification(s) of a former non EU Pharmacopoeial substance to fully comply with the Ph. Eur. or with a national pharmacopoeia of a Member State - Excipient/AS starting material B.III.2.a.2 - Change of specification(s) of a former non EU Pharmacopoeial substance to fully comply with the Ph. Eur. or with a national pharmacopoeia of a Member State - Excipient/AS starting material                                                                                                                                                                                                                                                                                                                 | 12/12/2019 | n/a |

<div style=\"page-break-after: always\"></div>

| IAIN/0006           | B.IV.1.a.1 - Change of a measuring or administration device - Addition or replacement of a device which is not an integrated part of the primary packaging - Device with CE marking   | 25/10/2019   | n/a   |                                   |
|---------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-------|-----------------------------------|
| IA/0005             | B.II.f.1.e - Stability of FP - Change to an approved stability protocol                                                                                                               | 15/10/2019   | n/a   |                                   |
| PSUSA/10732 /201902 | Periodic Safety Update EU Single assessment - damoctocog alfa pegol                                                                                                                   | 03/10/2019   | n/a   | PRAC Recommendation - maintenance |
| IA/0002             | B.II.e.7.a - Change in supplier of packaging components or devices (when mentioned in the dossier) - Deletion of a supplier                                                           | 28/03/2019   | n/a   |                                   |
| II/0001             | C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority                                         | 14/02/2019   | n/a   |                                   |